论文部分内容阅读
Objective.To test whether intramuscular,intranasal,intrarectal and intravagina l administration of HPV6b L 1 virus-like particlescould induce immune response in mice and to as sess whether intra-muscular and mucosal vaccination against HPV is feasible.Me thods.HPV6b L1proteins self-assembled into VLPs in Sf-9cell in vitro.Mic e were immunized on day0and21with50ìg HPV6b L1VLPs intramuscularly,int ranasally,intrarectally and intravagi-nally respectively.Sera were collected for testing IgG titer after a further7days and3months respec-tively.Results .After immunizations,all mice developed significant anti-HPV6b L1antibody titers in serum by7days after the second immunization.The titer of the serum I gG antibody against HPV6b L1VLPs in the intramuscularly immunized group was h igher than that in the intranasally,intrarectally and intravaginally immunized groups respectively,indicating that both muscular and mucosal administration of HPV6b L1VLPs can stimulate a systemic HPV-specific antibody response.Sera of the mice in the in-tramuscularly immunized group still maintained a high tit er of the serum IgG antibody against HPV6b L1VLPs 3months after the immunizat ion.Conclusion.The results demonstrated that the HPV6b L1VLPs maintain stro ng antigenicity.Immu-nization with HPV6b L1VLPs via intramuscular and mucos al routes,without adjuvant ,can elicit spe-cific antibody in sera.These fin dings suggest that the VLPs are able to induce protective antibodies.
Objective.To test whether intramuscular, intranasal, intrarectal and intravagina l administration of HPV6b L 1 virus-like particlescould induce immune response in mice and to as sess whether intra-muscular and mucosal vaccination against HPV is feasible. Me thods.HPV6b L1proteins self- assembled into VLPs in Sf-9cells in vitro. Mic e were immunized on day0 and 21 with 50 μg HPV6b L1 VLPs intramuscularly, int ranasally, intrarectally and intravagi-nally respectively. Sera were collected for testing IgG titer after a further 7 days and 3 months respec- tively. Results. After immunizations, all mice developed significant anti-HPV6b L1 antibody titers in serum by 7days after the second immunization. The titer of the serum IgG antibody against HPV6b L1 VLPs in the intramuscularly immunized groups was h igher than that in the intranasally, intrarectally and intravaginally immunized groups respectively, indicating that both muscular and mucosal administration of HPV6b L1VLPs can stimulate a systemic HPV-specific antibo dy response. Sera of the mice in the in-tramuscularly immunized group still maintained a high titer of the serum IgG antibody against HPV6b L1 VLPs 3 months after the immunizat ion. Confluence.The results showed that the HPV6b L1 VLPs maintain stro ng antigenicity. Immuno- nization with HPV6b L1VLPs via intramuscular and mucosal routes, without adjuvant, can elicit spe-cific antibody in sera. these fin dings suggest that the VLPs are able to induce protective antibodies.